Latest News

Lung Cancer

Immunotherapy, Molecular Testing Propel Dramatic Changes in Lung Cancer Care

2017 is poised to be another pivotal year in non–small cell lung cancer (NSCLC), given the exciting advances in field at the end of last year. In October 2016, the FDA approved pembrolizumab (Keytruda) for the frontline treatment of patients with metastatic NSCLC whose tumors have more than 50% PD-L1 expression. The agent was previously […]

Read More

Mutation-Targeted Therapy Slows Lung Cancer (NSCLC)

Patients with previously treated advanced non-small cell lung cancer (NSCLC) lived more than twice as long without disease progression when treated with a drug that targets a key resistance mutation versus standard chemotherapy, investigators reported. Treatment with the oral tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) led to a median progression-free survival (PFS) of 10.1 months […]

Read More

Lung Cancer Driver Discovery May Lead to Novel Therapy for Some Mesothelioma Patients

Lung adenocarcinoma, the most aggressive subtype of non-small cell lung cancer (NSCLC), comprises nearly 40 percent of lung cancer diagnoses. The KRAS gene is the most significant driver of this cancer, and is also found in some pleural mesothelioma cases. Researchers have been stymied by this tough gene that nearly always fights off treatments building […]

Read More

Olaratumab May Improve Disease Control in Certain Patients With GIST

Olaratumab had an acceptable safety profile and may improve disease control in patients with PDGFRα mutation-positive gastrointestinal stromal tumor (GIST), according to a study published in Annals of Oncology.1 This open-label, phase 2 study (ClinicalTrials.gov Identifier: NCT01316263) enrolled 30 previously treated patients with unresectable and/or metastatic GIST regardless of PDGFRα mutation status. All PDGFRα mutations […]

Read More

Imatinib and GISTs: Genomic Subtypes and Survival Outcomes

Some unresectable gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations respond to imatinib therapy and may extend a patient’s overall survival by as much as a decade, according to an article published in JAMA Oncology.1 Chemotherapy is notoriously ineffective for patients with a metastatic or unresectable GIST; it was shown, however, that GISTs with […]

Read More

Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer

Phase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The 50 women treated had progressed despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, […]

Read More

World Cancer Day 2017

A truly global event taking place every year on 4 February, World Cancer Day unites the world’s population in the fight against cancer. It aims to save millions of preventable deaths each year by raising awareness and education about the disease, pressing governments and individuals across the world to take action.  Currently, 8.2 million people […]

Read More

Precision medicine demonstrates benefit in late-stage cancer trial

A clinical trial carried out in a diverse set of advanced cancers is the first to demonstrate that use of precision medicine can slow down tumor regrowth.   The trial was carried out at the Gustave Roussy Cancer Campus (Paris, France) and these results were presented recently at the Molecular Analysis for Personalised Therapy Conference […]

Read More

Oncologica UK contributes to setting new guidelines for implementation of Next Generation Sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours. An expert opinion on behalf of IQN Path ASBL.

Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL The clinical demand for mutation detection within multiple genes from a single tumour sample requires molecular diagnostic laboratories to develop rapid, high-throughput, highly sensitive, accurate and parallel testing within tight budget […]

Read More

p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress.

This new discovery in relation to the molecular circuitry regulation the G1 cell cycle checkpoint provides a unique insight into why the new anti-cancer approach proposed using Cdc7 targeted anti-cancer therapies can act as powerful tumour killing agents but do not affect the normal cells of the body thereby circumventing the toxicity associated with conventional […]

Read More

Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatment

Using immunohistochemistry and flow cytometry to define phases of the cell cycle, this study shows that a high proportion of acute myeloid leukaemia (AML) blasts obtained from trephine biopsies are cycling, whereas >95% of peripheral blood-derived blasts are arrested in G1 . Results obtained from bone marrow aspirates are more similar to those from blood […]

Read More

Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint

PURPOSE Cdc7 is a serine/threonine kinase which is responsible for the ‘firing’ of replication origins leading to initiation of DNA replication. Inhibition or depletion of Cdc7 in normal cells triggers a DNA origin activation checkpoint causing a reversible G1 arrest. Here we investigate Cdc7 as a novel therapeutic target in pancreatic cancer. EXPERIMENTAL DESIGN Cdc7 […]

Read More